Ramin Ebrahimi1, Faisal G Bakaeen2, Abhimanyu Uberoi3, Abbas Ardehali3, Janet H Baltz4, Brack Hattler5, G Hossein Almassi6, Todd H Wagner7, Joseph F Collins8, Frederick L Grover9, A Laurie Shroyer10. 1. Greater Los Angeles VA Medical Center, Los Angeles, California. Electronic address: ebrahimi@ucla.edu. 2. The Michael E. DeBakey VA Medical Center, Houston, Texas; Department of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas. 3. Greater Los Angeles VA Medical Center, Los Angeles, California. 4. Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, Colorado. 5. Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, Colorado; Department of Medicine, University of Colorado School of Medicine at the Anschutz Medical Campus, Aurora, Colorado. 6. Department of Health Research and Policy, Stanford University, Stanford, California; Zablocki VA Medical Center, Milwaukee; and Medical College of Wisconsin, Milwaukee, Wisconsin. 7. Zablocki VA Medical Center, Milwaukee; and Medical College of Wisconsin, Milwaukee, Wisconsin; VA Palo Alto Health Economics Resource Center, Menlo Park, California. 8. Cooperative Studies Program Coordinating Center, VA Medical Center, Perry Point, Maryland. 9. Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, Colorado; Department of Surgery, University of Colorado School of Medicine at the Anschutz Medical Campus, Aurora, Colorado. 10. Northport VA Medical Center, Northport, New York.
Abstract
BACKGROUND:Clopidogrel use post coronary artery bypass grafting (CABG) has become more popular under the assumption that it improves graft patency. The purpose of this sub-analysis from the Randomized On and Off-Pump Bypass (ROOBY) trial is to evaluate the role of clopidogrel use post CABG to improve graft patency when added to standard aspirin therapy. METHODS: The ROOBY trial was a multi-center, randomized, controlled clinical trial that compared on-pump versus off-pump coronary artery bypass grafting (CABG). Clopidogrel use post CABG was left at the discretion of the operator. Detailed data regarding the use and timing of clopidogrel post CABG were collected prospectively, along with 1-year angiograms to evaluate graft status. RESULTS: Of the 2,203 subjects undergoing CABG, 953 patient records had complete clopidogrel use and 1-year angiographic data. Of these, 345 (36.2%) received clopidogrel post CABG prior to discharge. Compared with patients with no post-CABG clopidogrel use, baseline characteristics were similar for the clopidogrel group except for the following: lower preoperative aspirin use (80.2% vs 86.7%, p = 0.009); higher preoperative clopidogrel use (23.5% vs 14.0%, p < 0.001), less on-pump (35.9% vs 55.9%, p < 0.0001); and lower endoscopic vein harvesting (30.8% vs 42.5%, p < 0.001) rates. Overall 1-year graft patency rates were not different between the clopidogrel and no-clopidogrel groups (86.5% vs 85.3%, p = 0.43). Multivariable analyses did not alter these findings. CONCLUSIONS: This study suggests that routine post-CABG clopidogrel use may not translate to improved 1-year graft patency. Future studies appear warranted to better define the role of more aggressive antiplatelet therapy post CABG on graft patency and clinical outcomes.
RCT Entities:
BACKGROUND:Clopidogrel use post coronary artery bypass grafting (CABG) has become more popular under the assumption that it improves graft patency. The purpose of this sub-analysis from the Randomized On and Off-Pump Bypass (ROOBY) trial is to evaluate the role of clopidogrel use post CABG to improve graft patency when added to standard aspirin therapy. METHODS: The ROOBY trial was a multi-center, randomized, controlled clinical trial that compared on-pump versus off-pump coronary artery bypass grafting (CABG). Clopidogrel use post CABG was left at the discretion of the operator. Detailed data regarding the use and timing of clopidogrel post CABG were collected prospectively, along with 1-year angiograms to evaluate graft status. RESULTS: Of the 2,203 subjects undergoing CABG, 953 patient records had complete clopidogrel use and 1-year angiographic data. Of these, 345 (36.2%) received clopidogrel post CABG prior to discharge. Compared with patients with no post-CABG clopidogrel use, baseline characteristics were similar for the clopidogrel group except for the following: lower preoperative aspirin use (80.2% vs 86.7%, p = 0.009); higher preoperative clopidogrel use (23.5% vs 14.0%, p < 0.001), less on-pump (35.9% vs 55.9%, p < 0.0001); and lower endoscopic vein harvesting (30.8% vs 42.5%, p < 0.001) rates. Overall 1-year graft patency rates were not different between the clopidogrel and no-clopidogrel groups (86.5% vs 85.3%, p = 0.43). Multivariable analyses did not alter these findings. CONCLUSIONS: This study suggests that routine post-CABG clopidogrel use may not translate to improved 1-year graft patency. Future studies appear warranted to better define the role of more aggressive antiplatelet therapy post CABG on graft patency and clinical outcomes.
Authors: Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax Journal: Nat Rev Cardiol Date: 2016-05-19 Impact factor: 32.419
Authors: Paulo Roberto L Prates; Judson B Williams; Rajendra H Mehta; Susanna R Stevens; Laine Thomas; Peter K Smith; L Kristin Newby; Renato A K Kalil; John H Alexander; Renato D Lopes Journal: Braz J Cardiovasc Surg Date: 2016-04
Authors: Scott D Nei; Kyle S Wamsley; Kristin C Mara; John M Stulak; Joseph J Zieminski Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 3.512